뒤로
Vioquest Pharmaceuticals Inc(VOQP) 가격
VOQP 주가 차트
VOQP 수입
Vioquest Pharmaceuticals Inc
$0
0%
$0
종가: Jan 27, 16:00:00 GMT-5
$0
0%
$0
프리마켓: Jan 28, 05:03:40 GMT-5
아직 데이터 없음Earnings FAQ
VOQP의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Vioquest Pharmaceuticals Inc VOQP의 지난 분기 매출 실적은 어땠나요?
Vioquest Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
Vioquest Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
Vioquest Pharmaceuticals Inc는 언제 수익을 보고하나요?
Vioquest Pharmaceuticals Inc의 예상 수익은 얼마인가요?
Vioquest Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.003
시가
$0.003
일일 범위
$0 - $0.003
52주 범위
$0 - $0.003
거래량
100
평균 거래량
0
EPS(TTM)
-2.10
배당수익률
--
시가총액
$16.3K
VOQP란 무엇인가요?
VioQuest Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug therapies for the molecular basis of cancer and side effects of cancer treatment. The company is headquartered in Basking Ridge, New Jersey and currently employs 3 full-time employees. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.